文献速递白血病

去棕榈酰化重编程FLT3-ITD信号并加剧白血病进展

Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression.
PubMed 文献 · Blood · 2021-01-01

本研究揭示FLT3-ITD由棕榈酰转移酶ZDHHC6介导S-棕榈酰化,使其滞留于内质网并激活STAT5。破坏棕榈酰化使FLT3-ITD转位至质膜,额外激活AKT和ERK,并加速白血病进展。抑制去棕榈酰化与吉瑞替尼协同抑制原代FLT3-ITD+ AML细胞生长。

要点

  • ZDHHC6介导的棕榈酰化使FLT3-ITD滞留内质网并限制其表面表达与信号。
  • 破坏棕榈酰化重编程FLT3-ITD信号,激活AKT/ERK并加剧白血病进展。
  • 抑制去棕榈酰化与吉瑞替尼协同抑制原代FLT3-ITD+ AML细胞生长。

核心结论

  • FLT3-ITD的S-棕榈酰化决定其亚细胞定位与信号输出,去棕榈酰化可重编程信号并加剧白血病进展。

研究设计与样本

  • 研究在异种移植受体小鼠模型和原代人类AML细胞中开展,未报告样本量。

主要发现

  • ZDHHC6介导FLT3-ITD的S-棕榈酰化,破坏棕榈酰化使FLT3-ITD转位至质膜并额外激活AKT和ERK通路。
  • 破坏棕榈酰化增加FLT3-ITD介导的白血病进展(异种移植小鼠模型)。
  • 原代人类AML细胞中FLT3蛋白存在棕榈酰化,ZDHHC6介导的棕榈酰化限制FLT3-ITD表面表达、信号及原代FLT3-ITD+ AML的集落生长。
  • 药理学抑制FLT3-ITD去棕榈酰化与FDA批准的FLT3抑制剂吉瑞替尼协同削弱原代FLT3-ITD+ AML细胞生长。

临床怎么用

  • 靶向去棕榈酰化可能作为FLT3-ITD+白血病的新治疗策略,并与吉瑞替尼联合使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Internal tandem duplication within FLT3 (FLT3-ITD) is one of the most frequent mutations in acute myeloid leukemia (AML) and correlates with a poor prognosis. Whereas the FLT3 receptor tyrosine kinase is activated at the plasma membrane to transduce PI3K/AKT and RAS/MAPK signaling, FLT3-ITD resides in the endoplasmic reticulum and triggers constitutive STAT5 phosphorylation. Mechanisms underlying this aberrant FLT3-ITD subcellular localization or its impact on leukemogenesis remain poorly established. In this study, we discovered that FLT3-ITD is S-palmitoylated by the palmitoyl acyltransferase ZDHHC6. Disruption of palmitoylation redirected FLT3-ITD to the plasma membrane and rewired its downstream signaling by activating AKT and extracellular signal-regulated kinase pathways in addition to STAT5. Consequently, abrogation of palmitoylation increased FLT3-ITD-mediated progression of leukemia in xenotransplant-recipient mouse models. We further demonstrate that FLT3 proteins were palmitoylated in primary human AML cells. ZDHHC6-mediated palmitoylation restrained FLT3-ITD surface expression, signaling, and colonogenic growth of primary FLT3-ITD+ AML. More important, pharmacological inhibition of FLT3-ITD depalmitoylation synergized with the US Food and Drug Administration-approved FLT3 kinase inhibitor gilteritinib in abrogating the growth of primary FLT3-ITD+ AML cells. These findings provide novel insights into lipid-dependent compartmentalization of FLT3-ITD signaling in AML and suggest targeting depalmitoylation as a new therapeutic strategy to treat FLT3-ITD+ leukemias.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lv K, Ren JG, Han X, et al. Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression. Blood. 2021. PMID: 34111291. doi:10.1182/blood.2021011582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。